NCT00978523View on ClinicalTrials.gov

Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Solid TumorsLymphoma
Interventions
DRUG

AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)

Oral, dose-escalation

Trial Locations (3)

43210

The Ohio State University - Comprehensive Cancer Center, Columbus

85258

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors

Lead Sponsor

Arno Therapeutics
All Listed Sponsors
lead

Arno Therapeutics

INDUSTRY

NCT00978523 - Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter